Results 31 to 40 of about 593,039 (291)

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari, Regina Hadi Putri, Fatimah Assyifa, Judith Spijkerman, Gertjan Johannes Kaspers, Susi Susanah   +5 more
wiley   +1 more source

29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients

Dermatology Reports
Background: Although immunotherapy has revolutionized melanoma management, there is an urgent need to find useful biomarkers to follow disease evolution and response to therapy.
Italian Melanoma Intergroup
doaj   +1 more source

Impact of Initial Treatment Setting on Survival in Relapsed Pediatric and AYA Bone Sarcomas: A Secondary Analysis of a Prospective Clinical Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Outcomes in relapsed or refractory pediatric and AYA bone sarcomas remain poor, and the impact of early referral to specialized sarcoma centers on survival is unclear. Early centralization of care may improve local and systemic treatment quality, but evidence in this population is limited.
Justyna Antoniuk‐Majchrzak, Katarzyna Bilska, Tomasz Koziński, Jadwiga Węcławek‐Tompol, Dorota Sega‐Pondel, Radosław Chaber, Wanda Badowska, Katarzyna Rosłan, Hanna Koseła‐Paterczyk, Anna Raciborska   +9 more
wiley   +1 more source

31 | Effectiveness and safety of adjuvant combo-targeted and immunotherapy in melanoma patients

Dermatology Reports
Background: Adjuvant combo-targeted therapy (TT) and immunotherapy (IT) reduced relapse risk (HR=0.50) in fully resected stage III melanoma, without improving overall survival (OS). Real-world data are crucial to assess their effectiveness and safety in
Italian Melanoma Intergroup
doaj   +1 more source

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis [PDF]

, 2013
The role of apoptosis in melanoma pathogenesis and chemoresistance is poorly characterized. Mutations in TP53 occur infrequently, yet the TP53 apoptotic pathway is often abrogated.
Graf, M, Mesher, D, Francesca Moretti, Chiorino, G, A. Chikh, Costanzo, A, M. Graf, D. Bergamaschi, Leigh, IM, Cerio, R, Maria Scatolini, Chong, SLP, C. M. Proby, Anissa Chikh, Antonio Costanzo, Matin, RN, Moretti, F, COSTANZO, ANTONIO, Charlotte M. Proby, Valentina Senatore, C. A. Harwood, Senatore, V, I. M. Leigh, D. Mesher, Harwood, CA, Catherine A. Harwood, R. N. Matin, Stephanie Law Pak Chong, Paolo Sanza’, Rino Cerio, R. Cerio, Bergamaschi, D, David Mesher, P. Sanza', M. Scatolini, Irene M. Leigh, S. L. Pak, Rubeta N. Matin, Proby, CM, V. Senatore, Daniele Bergamaschi, F. Moretti, Chikh, A, Sanza', P, Scatolini, M, Giovanna Chiorino, G. Chiorino, Manuela Graf   +47 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup

Dermatology Reports
Introduction: Non-V600E/K BRAF mutations have been reported in melanoma, but data on their clinical relevance are conflicting. This study investigated the distribution, prognostic role and functional impact of rare BRAF mutations in melanoma.
Italian Melanoma Intergroup
doaj   +1 more source

Heterogeneity in Melanoma

Cancers, 2022
There is growing evidence that tumour heterogeneity has an imperative role in cancer development, evolution and resistance to therapy. Continuing advancements in biomedical research enable tumour heterogeneity to be observed and studied more critically.
Mei Fong Ng, Jacinta L. Simmons, Glen M. Boyle   +2 more
openaire   +5 more sources

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study

Dermatology Reports
Background: Ipilimumab plus nivolumab (COMBO) is the standard treatment in patients with asymptomatic melanoma brain metastases (MBM) (1)(2)(3). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO with or
Italian Melanoma Intergroup
doaj   +1 more source